Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients with confirmed diagnosis.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product delivery across regulated markets.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

- Acute hereditary angioedema type I: rapid reduction of subcutaneous and airway edema. - Acute hereditary angioedema type II: prompt relief of swelling episodes. - Hereditary angioedema attacks related to C1‑esterase inhibitor deficiency: improves airway patency and reduces pain.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: new swelling episodes unrelated to HAE. - Urticaria: hives or skin rash. - Hypotension: sudden drop in blood pressure. - Severe injection‑site necrosis: tissue damage at the site. - Thrombotic events: rare clot formation.

Before using Icatibant, consider the following safety measures.

- Hypersensitivity: do not use in patients with known allergy to icatibant or any excipients. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; it is unknown whether the drug passes into breast milk. - Renal impairment: consider dose adjustment and monitor renal function. - Concomitant ACE inhibitors: monitor for enhanced bradykinin effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin‑mediated effects, raising risk of angioedema. - Neprilysin inhibitors: elevate bradykinin concentrations, potentially reducing efficacy. - C1‑esterase inhibitor concentrates: concurrent use may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may increase frequency of HAE attacks. - Diuretics: can affect fluid balance; monitor blood pressure. - Other subcutaneous biologics: observe for overlapping injection‑site reactions.